TRAIL Compounds for Radiation Lung Injury

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cancer treatment often results in undesirable toxic side effects, particularly radiation-induced pneumonitis and fibrosis, which are debilitating and limit the effectiveness of therapies due to their impact on surrounding tissues and organs.

Innovation Solution

Administering an effective amount of a TRAIL compound, such as PEGylated trimeric TRAIL (TLY012) or TRAIL-inducing Compound #10 (TIC10/ONC201), to modulate TRAIL/DR5 signaling and reduce toxic side effects by protecting against radiation-induced lung injury.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If radiation therapy is administered to treat cancer, then tumor cells are effectively killed, but surrounding healthy tissues and organs suffer toxic damage causing pneumonitis and fibrosis

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidradiation-induced lung injury

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces TRAIL compounds as intermediary substances that selectively mediate between radiation therapy and cancer cells. These compounds bind to death receptors on cancer cells to induce apoptosis, while protecting healthy lung tissues from radiation damage through anti-inflammatory effects, thus resolving the contradiction between effective cancer killing and healthy tissue preservation

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies TRAIL compounds locally to the tumor site and surrounding tissues at controlled doses. This localized application ensures high concentration at the target site for effective cancer cell killing while limiting systemic exposure and protecting distant healthy organs from radiation-induced toxicity

Inventive Principle:

Principle #3Local quality

2Productivity

If high dose radiation is used to eliminate tumors, then cancer control is improved, but lung fibrosis and pneumonitis severity increases

Engineering Contradiction:

Improvetumor elimination rateVSAvoidinflammation and fibrosis

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful radiation-induced inflammatory response into a beneficial effect by administering TRAIL compounds that modulate the immune response. The compounds transform the damaging inflammation into a controlled anti-tumor immune activation while protecting healthy lung tissues, effectively converting radiation harm into therapeutic benefit

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If radiation therapy is administered to achieve curative results, then patient survival is improved, but quality of life deteriorates due to debilitating side effects

Engineering Contradiction:

Improvepatient survival rateVSAvoidpatient quality of life

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies TRAIL compounds preliminarily before or concurrently with radiation therapy to prevent the development of severe side effects. This preliminary protective action reduces inflammation and fibrosis before they can occur, allowing patients to maintain better quality of life throughout and after treatment while still achieving curative results

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Short-term treatment with TRAIL pathway agonists effectively rescues mice from severe inflammation and lethality, reducing alveolar-wall thickness, fibrosis, and improving oxygen saturation, while maintaining anti-tumor efficacy of radiation therapy.

Implementation Method 1

TRAIL-R, the only proapoptotic death-signaling receptor for TRAIL in the mouse, suppresses inflammation and tumorigenesis

Methodology Applied

Scientific EffectApoptosis:

Implementation Method 2

TRAIL-R suppresses inflammation and tumorigenesis. Histological evaluation of moribund irradiated TRAIL-R-/- animals showed hallmarks of bronchopneumonia as well as tumor formation with increased NF-κB p65 expression

Methodology Applied

Scientific EffectInflammation suppression:

Data Source

PatentUS20230414715A1Trail compounds for reducing cancer treament side effects

Publication Date: 2023.12.28 BROWN UNIVERSITY

AI summary

A method of reducing toxic side effects in a subject undergoing cancer treatment is described. The method includes administering an effective amount of a TRAIL compound to the subject.